+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Regression of brain metastases from breast cancer with eribulin: a case report

Regression of brain metastases from breast cancer with eribulin: a case report

Bmc Research Notes 6: 541

Eribulin is a recently approved new therapeutic option for patients with metastatic breast cancer. According to several reports, eribulin has limited ability to cross the blood brain barrier. Recently, capecitabine and eribulin have been recognized as drugs with similar application for patients with advanced breast cancer. Although there have been several case reports describing the efficacy of capecitabine against brain metastases, no report of eribulin demonstrating efficacy for brain metastases exists today. We describe a case of a 57-year-old Japanese woman who was diagnosed with breast cancer stage IV metastasized to multiple organs including liver and lung. After she received 3 regimens, she showed evidence of brain metastases, and whole brain radiation therapy was performed. Lapatinib and capecitabine was then administered as fourth-line chemotherapy, but the patient was hospitalized due to the exacerbation of interstitial pneumonitis and progression of brain and liver metastases. To control the systemic disease, eribulin was commenced as fifth-line chemotherapy. One month later, a significant response of brain metastases had been achieved, and this response has persisted for the last 4 months. We now describe a remarkable antitumor effect of eribulin against brain metastases from breast cancer. This case is the first report which indicates potential treatment of brain metastases using this medication. This report suggests that eribulin treatment may be beneficial for breast cancer patients with brain metastases progressing after whole brain radiation therapy. However, further clinical studies are warranted to determine the clinical effect of eribulin in brain metastases.

(PDF emailed within 0-6 h: $19.90)

Accession: 055446828

Download citation: RISBibTeXText

PMID: 24350786

DOI: 10.1186/1756-0500-6-541

Related references

A case of brain metastases from breast cancer treated with whole-brain radiotherapy and eribulin mesylate. Case Reports in Oncological Medicine 2012: 537183, 2012

Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series. Breast Cancer 9: 19-24, 2015

Regression of pulmonary metastases of a breast cancer. Report of a case of spontaneous and temporary regression after radical mastectomy. Archives of Surgery 84: 574-577, 1962

Experience with eribulin in patients with breast cancer and cutaneous metastases: case studies. Future Oncology 14(7s): 37-44, 2018

A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate. Future Oncology 9(10): 1437-1442, 2014

HER2-positive recurrent breast cancer and metastases of breast cancer, including life-threatening metastases to the brain and dura mater a case effectively treated with lapatinib plus capecitabine before whole brain radiotherapy. International Cancer Conference Journal 2(1): 9-13, 2013

Long response to eribulin in breast cancer: a case report. Future Oncology 11(15 Suppl): 3-8, 2016

Letrozole for brain and scalp metastases from breast cancer--a case report. Breast 15(3): 440-442, 2005

Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report. Future Oncology 13(11s): 51-54, 2017

Influence of brain metastases on the chemotherapeutic management of breast cancer: a case report. Mount Sinai Journal of Medicine, New York 44(4): 515-520, 1977

Response of brain metastases from breast cancer to megestrol acetate: a case report. Journal of Neuro-Oncology 24(3): 299-301, 1995

Chemotherapy-induced complete regression of choroidal metastases and subsequent isolated leptomeningeal carcinomatosis in advanced breast cancer: a case report and literature review. Journal of Neuro-Oncology 47(2): 161-165, 2000

Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports. Journal of Breast Cancer 19(2): 214-217, 2016

Radiotherapy and Eribulin Mesylate for Mediastinal Node Metastasis from Breast Cancer-A Case Report. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 45(13): 2177-2179, 2019

Presentation and course of brain metastases from breast cancer in a paranoid-schizophrenic patient: A case report. Cases Journal 1(1): 195, 2008